Wanbury Limited (NSE:WANBURY)

Market Cap	7.13B -17.2%
Revenue (ttm)	6.76B +7.2%
Net Income	498.37M -0.6%
EPS	13.87 -7.3%
Shares Out	n/a
PE Ratio	14.70
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	234,633
Open	201.15
Previous Close	200.71
Day's Range	200.99 - 211.89
52-Week Range	161.50 - 358.85
Beta	0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 4, 2026

About Wanbury

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. It offers formulations for anti-infectives, pain and analgesics, gastroenterology, rheumatology, respiratory, gynecology, and central nervous system, as well as for vitamins, minerals, and nutrition. The company also provides API products for antidiabetics, antidepressants, anti-histaminic, anaesthetic, anti-inflammatory, anti-coagulant, GERD, and gastric ulcer therapy, as well as antitussives and analgesics. Its API por...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 1,200
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: WANBURY

Financial Performance

In fiscal year 2026, Wanbury's revenue was 6.50 billion, an increase of 8.47% compared to the previous year's 6.00 billion. Earnings were 661.35 million, an increase of 116.62%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error